New Developments in the Standardization of Total Prostate-Specific Antigen

launched assays for the measurement of total prostate-specific antigen, i.e., IMx Total PSA (Abbott), Elecsys PSA (Roche), and IMMULITE 3rd Generation PSA (DPC). Design and methods: For accuracy assessment two reference materials were applied namely, Stanford 90:10 PSA Calibrator and Certified Reference Material 613 Prostate-Specific Antigen. Dilutions of these preparations were analyzed with all assays. In addition, clinical specimens from known prostate cancer or benign prostate hyperplasia patients and samples taken from an ongoing prostate cancer screening study were used for comparison. Results: Application of the Stanford Calibrator revealed results well within 10% of the calculated values for all assays. Regarding the CRM Calibrator only the IMx Total PSA proved to approach the line of identity. The IMMULITE results differed about 40% and the Elecsys about 18% from the calculated values. The comparison with clinical specimens showed statistically different results for the combination IMMULITE-IMx a nd tor IMMUUTE-Elecsys. The regression lines for both collections were: y(IMx) = 0.86x(IMMULITE) + 0.12 (n= 104, r= 0.970, Sy/x = 0.883 mug/L) and y(Elecsys) = 0.98 x(IMMULITE) + 0.38 (n= 97, r = 0.976, Sy/x = 0.733 ug/L). In the lower measuring range (PSA < 5.0 ug/L) as measured with the screening samples (n = 43), these differences were less pronounced. Conclusion: In analytical sense a difference was found for both reference preparations in the assays studied. Clinically, despite improvements in methodology, results for total prostate-specific antigen are still not interchangeable. The possible consequences need to be elaborated. Copyright © 1999 The Canadian Society of Clinical Chemists